After years of boom times, the U.S. biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation.
In this Xconomy Special Report, our veteran biotech journalists Alex Lash and Ben Fidler bring you deep insights, based on conversations with key industry leaders, on what 2019 and beyond hold for biopharmaceutical companies. In this Report, you’ll learn:
Here’s a taste of what Greenwood and Celniker told us:
Greenwood: “I view the current time as an existential threat to the industry.”
Celniker: “We’ve seen the volatility. But we’re less focused on the volatility and more on building these companies so that they can endure tough markets or take advantage of IPO windows when they’re open.”